secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-003670
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference
--------------------------------------------------------------------------------

- Attending 41st Annual J.P. Morgan Healthcare Conference starting January 9, 2023 in San Francisco.
- Updated corporate presentation filed as Exhibit 99.1 for investor meetings.
- Forward-looking statements caution about risks including clinical trials and regulatory approvals.
- Company's product candidate belzupacap sarotalocan for choroidal melanoma is highlighted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/0001193125-23-003670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/d377715d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-003670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer